cytarabine and fludarabine phosphate

cytarabine has been researched along with fludarabine phosphate in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19902 (20.00)18.7374
1990's1 (10.00)18.2507
2000's5 (50.00)29.6817
2010's2 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bigner, DD; Friedman, HS; Schold, SC1
Gandhi, V; Keating, MJ; Nowak, B; Plunkett, W1
Bosanquet, AG1
Akutsu, M; Bai, L; Furukawa, Y; Ichikawa, A; Kano, Y; Kon, K; Suzuki, K; Tsunoda, S1
Child, JA; Johnson, PW; Johnson, SA; Morgan, GJ; Prentice, AG; Rule, S; Smith, GM; Tollerfield, SM; Wareham, E1
Avramis, IA; Avramis, VI; Laug, WE; Sausville, EA1

Reviews

1 review(s) available for cytarabine and fludarabine phosphate

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for cytarabine and fludarabine phosphate

ArticleYear
FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Leukemia & lymphoma, 2000, Volume: 37, Issue:3-4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pilot Projects; Recurrence; Salvage Therapy; Survival Rate; Vidarabine Phosphate

2000

Other Studies

8 other study(ies) available for cytarabine and fludarabine phosphate

ArticleYear
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice.
    Cancer research, 1986, Volume: 46, Issue:1

    Topics: Animals; Azacitidine; Brain Neoplasms; Cell Line; Cytarabine; Doxorubicin; Humans; Medulloblastoma; Melphalan; Mice; Mice, Nude; Mitoguazone; Neoplasm Transplantation; Nitrosourea Compounds; Skin Neoplasms; Vidarabine Phosphate

1986
Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
    Blood, 1989, Nov-01, Volume: 74, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Cytarabine; Drug Evaluation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Vidarabine Phosphate

1989
Re: V.I. Avramis et al., Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a Phase I/II study in pediatric patients with relapsed leukemias. Clin. Can
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Humans; Leukemia; Terminology as Topic; Vidarabine; Vidarabine Phosphate

1999
In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
    Leukemia, 2000, Volume: 14, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Survival; Cyclophosphamide; Cytarabine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Hydroxyurea; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Methotrexate; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine; Vidarabine Phosphate; Vincristine

2000
Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:4

    Topics: Adamantane; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Hydroquinones; Imatinib Mesylate; Leukemia-Lymphoma, Adult T-Cell; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vascular Endothelial Growth Factor A; Vidarabine Phosphate

2003